PL2125019T3 - Ulepszone kompozycje lecznicze zawierające buprenorfinę i naltrekson - Google Patents

Ulepszone kompozycje lecznicze zawierające buprenorfinę i naltrekson

Info

Publication number
PL2125019T3
PL2125019T3 PL08709412T PL08709412T PL2125019T3 PL 2125019 T3 PL2125019 T3 PL 2125019T3 PL 08709412 T PL08709412 T PL 08709412T PL 08709412 T PL08709412 T PL 08709412T PL 2125019 T3 PL2125019 T3 PL 2125019T3
Authority
PL
Poland
Prior art keywords
naltrexone
buprenorphine
medicinal compositions
improved medicinal
improved
Prior art date
Application number
PL08709412T
Other languages
English (en)
Polish (pl)
Inventor
Christopher Bourne Chapleo
Neil Hyde
Original Assignee
Indivior Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37965733&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2125019(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Indivior Uk Ltd filed Critical Indivior Uk Ltd
Publication of PL2125019T3 publication Critical patent/PL2125019T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PL08709412T 2007-03-01 2008-02-15 Ulepszone kompozycje lecznicze zawierające buprenorfinę i naltrekson PL2125019T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0703966A GB2447014A (en) 2007-03-01 2007-03-01 Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
PCT/GB2008/000521 WO2008104735A1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and naltrexone
EP08709412.4A EP2125019B1 (en) 2007-03-01 2008-02-15 Improved medicinal compositions comprising buprenorphine and naltrexone

Publications (1)

Publication Number Publication Date
PL2125019T3 true PL2125019T3 (pl) 2014-08-29

Family

ID=37965733

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08709412T PL2125019T3 (pl) 2007-03-01 2008-02-15 Ulepszone kompozycje lecznicze zawierające buprenorfinę i naltrekson

Country Status (21)

Country Link
US (1) US8912211B2 (enExample)
EP (1) EP2125019B1 (enExample)
JP (1) JP5577101B2 (enExample)
KR (1) KR20090115861A (enExample)
CN (1) CN101622014A (enExample)
AR (1) AR065580A1 (enExample)
AU (1) AU2008220620A1 (enExample)
BR (1) BRPI0807902A2 (enExample)
CA (1) CA2678481C (enExample)
CL (1) CL2008000608A1 (enExample)
DK (1) DK2125019T3 (enExample)
ES (1) ES2475734T3 (enExample)
GB (1) GB2447014A (enExample)
HR (1) HRP20140592T1 (enExample)
MX (1) MX2009009132A (enExample)
PE (1) PE20081799A1 (enExample)
PL (1) PL2125019T3 (enExample)
PT (1) PT2125019E (enExample)
TW (1) TW200836737A (enExample)
WO (1) WO2008104735A1 (enExample)
ZA (1) ZA200905689B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9205081B2 (en) 2010-04-29 2015-12-08 Allodynic Therapeutics, Llc Combinations of opiod/TLR4 antagonist and a cyclooxygenase (COX) inhibitor for use in the treatment of pain
US9095548B2 (en) 2010-04-29 2015-08-04 Allodynic Therapeutics, Llc Combinations of opioid/TLR4 antagonists and acetyl-para-aminophenol (APAP) for use in the treatment of pain
ES2566828T3 (es) * 2010-09-21 2016-04-15 Purdue Pharma L.P. Análogos de buprenorfina como agonistas y/o antagonistas del receptor opioide
WO2014160077A1 (en) * 2013-03-13 2014-10-02 Allodynic Therapeutics, Llc Compositions to reduce pain comprising an opioid/toll-like receptor 4 antagonist, dextro enantiomers thereof, and methods of use therefor
ES2703623T3 (es) * 2013-06-28 2019-03-11 Purdue Pharma Lp Antagonistas opioides para uso en el tratamiento de una arritmia inducida por analgésicos opioides
EP3043777B1 (en) 2013-09-10 2020-04-22 Fresh Cut Development, LLC Sublingual buprenorphine spray
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US10617686B2 (en) 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
CA2954370A1 (en) 2014-07-08 2016-01-14 Insys Pharma, Inc. Sublingual naloxone spray
US20180147201A1 (en) 2016-10-31 2018-05-31 Allodynic Therapeutics, Llc Combinations of opioid/tlr4 antagonists and acetaminophen for use in the treatment of emotional pain and insomnia
US12343340B2 (en) 2020-12-31 2025-07-01 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain
US11752143B2 (en) 2020-12-31 2023-09-12 Soin Therapeutics Llc Methods of using low dose naltrexone to treat chronic pain

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US572149A (en) * 1896-12-01 Tobacco-cutting machine
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5272149A (en) 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
WO1999032120A1 (en) * 1997-12-22 1999-07-01 Euro-Celtique, S.A. A method of preventing abuse of opioid dosage forms
AR031682A1 (es) 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
EP2517710B1 (en) * 2000-02-08 2015-03-25 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine

Also Published As

Publication number Publication date
KR20090115861A (ko) 2009-11-09
ZA200905689B (en) 2010-10-27
GB2447014A (en) 2008-09-03
HRP20140592T1 (hr) 2014-09-12
CA2678481A1 (en) 2008-09-04
JP5577101B2 (ja) 2014-08-20
GB0703966D0 (en) 2007-04-11
US20100120812A1 (en) 2010-05-13
CN101622014A (zh) 2010-01-06
DK2125019T3 (da) 2014-06-30
TW200836737A (en) 2008-09-16
AU2008220620A1 (en) 2008-09-04
US8912211B2 (en) 2014-12-16
EP2125019A1 (en) 2009-12-02
BRPI0807902A2 (pt) 2014-06-17
PT2125019E (pt) 2014-07-11
JP2010520183A (ja) 2010-06-10
WO2008104735A1 (en) 2008-09-04
ES2475734T3 (es) 2014-07-11
AR065580A1 (es) 2009-06-17
CA2678481C (en) 2014-11-18
EP2125019B1 (en) 2014-04-09
CL2008000608A1 (es) 2008-10-03
MX2009009132A (es) 2009-09-03
PE20081799A1 (es) 2008-12-18

Similar Documents

Publication Publication Date Title
ZA200905689B (en) Improved medicinal compositions comprising buprenorphine and naltrexone
ZA200905691B (en) Improved medicinal compositions comprising buprenorphine and naloxone
ZA201106831B (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
IL242883B (en) Aryl-amino and heteroaryl-amino converted deoxazolines and pharmaceutical preparations containing them
EP2035014A4 (en) FUCOIDANE PREPARATIONS AND METHODS
ZA200804355B (en) Pharmaceutical compositions comprising buprenorphine
ZA201203709B (en) Immunogenic compositions and methods
ZA201001300B (en) Antigen-asjuvant compositions and methods
PL2224917T3 (pl) Kompozycja zawierająca nikotynę oraz opipramol i jej zastosowanie
AP3441A (en) Pharmaceutical compositions comprising hydromorphone and naloxone
ZA200807614B (en) Buprenorphine derivatives and uses thereof
GB0721291D0 (en) Methods and compositions
ZA200905692B (en) Improved medicinal compositions comprising buprenorphine and nalmefene
GB0719526D0 (en) Compositions and methods
HK1165319A (en) Immediate release pharmaceutical compositions comprising oxycodone and naloxone
GB0906046D0 (en) Nalmefene compositions and their therapeutic use
GB0906045D0 (en) Nalmefene compositions and their therapeutic use
GB0906042D0 (en) Nalmefene compositions and their therapeutic use
GB0906043D0 (en) Nalmefene compositions and their therapeutic use
GB0906044D0 (en) Nalmefene compositions and their therapeutic use
GB0717683D0 (en) Compositions and methods
GB0723775D0 (en) Methods and compositions
HK1180589A (en) Pharmaceutical compositions comprising hydromorphone and naloxone